Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus Ltd (ASX:RGS) are pleased to provide the Company's Annual Report for 2015 to shareholders.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $3.4m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2015 financial year.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported its 2015 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cellbased therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the first patient has been enrolled and treated in the STEP (Safety, Tolerability and Efficacy of Progenza) trial, the first clinical trial of Progenza, the company's allogeneic stem cell product for the treatment of knee osteoarthritis.
Regeneus (ASX:RGS), a clinical stage regenerative medicine company, has received ethics approval to commence its first-in-human trial for a personalised therapeutic cancer vaccine that is aimed at harnessing the body's own immune system to fight cancer cells.
Regeneus (ASX:RGS), a clinical stage regenerative medicine company focused on the development of cell therapies, announced today that it has received ethics approval for a clinical trial of its new off-the-shelf allogeneic stem cell treatment, known as Progenza, for patients with knee osteoarthritis.
Organised by the Alliance for Regenerative Medicine (ARM), the 3rd Annual Regenerative Medicine Investor Day was held on March 25th 2015 in New York City.
Regeneus (ASX:RGS) announced today that it has achieved a key manufacturing milestone for its proprietary "off-the-shelf" allogeneic stem cell therapy product, Progenza.
Regeneus Ltd (ASX:RGS) announced today that John Martin, CEO, will present at the 3rd Annual Regenerative Medicine Investor Day to be held Wednesday, March 25, 2015 in New York City.
Regenerative medicine company, Regeneus (ASX:RGS) announced today that it has successfully completed a preclinical study to support its first-in-human safety study of Progenza, its allogeneic, off-theshelf stem cell product for osteoarthritis (OA).
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
